Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$126.58
+1.5%
$127.47
$107.43
$150.57
$5.59B0.841.36 million shs1.14 million shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$126.58
+1.5%
$127.47
$107.43
$150.57
$5.59B0.841.36 million shs1.14 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$28.54
+2.6%
$29.77
$23.15
$170.47
$11.03B2.237.39 million shs7.71 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.67
+3.9%
$7.04
$4.29
$23.86
$1.07B3.158.37 million shs5.23 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.41
+2.6%
$24.44
$20.92
$31.54
$138.44B0.6740.88 million shs53.88 million shs
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
$82.95
+1.3%
$81.91
$66.66
$105.47
$5.27B18.97 million shs9.58 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+0.10%+3.59%-4.25%-9.27%-2.82%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+0.10%+3.59%-4.25%-9.27%-2.82%
Moderna, Inc. stock logo
MRNA
Moderna
+1.31%+8.08%-10.60%-31.68%-75.08%
Novavax, Inc. stock logo
NVAX
Novavax
-4.18%+2.72%-8.29%-27.13%+49.65%
Pfizer Inc. stock logo
PFE
Pfizer
+3.30%+5.59%-5.56%-10.68%-7.21%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
+0.63%+5.46%-2.99%-11.56%-4.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
4.3377 of 5 stars
4.01.00.04.63.32.50.6
Novavax, Inc. stock logo
NVAX
Novavax
3.6226 of 5 stars
3.21.00.04.73.10.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9766 of 5 stars
3.33.04.24.33.13.33.1
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.69
Moderate Buy$126.58N/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.69
Moderate Buy$126.58N/A
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$58.70105.68% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$18.00169.87% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.6421.44% Upside
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
2.76
Moderate Buy$82.95N/A

Current Analyst Ratings Breakdown

Latest IBB, XBI, MRNA, PFE, NVAX, and IBB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/17/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/9/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
3/27/2025
Pfizer Inc. stock logo
PFE
Pfizer
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/18/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/12/2025
Pfizer Inc. stock logo
PFE
Pfizer
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.45N/AN/A$28.33 per share1.01
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.57N/AN/A($6.04) per share-1.10
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.18$3.83 per share6.38$15.81 per share1.54
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/A25.09N/AN/AN/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/A25.09N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$1.33N/A83.382.85-32.18%N/A-17.05%5/9/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4117.318.060.6412.62%19.47%8.09%N/A
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/A11.47N/AN/AN/AN/AN/A

Latest IBB, XBI, MRNA, PFE, NVAX, and IBB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.19N/AN/AN/A$204.08 millionN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
2/27/2025Q4 2024
Novavax, Inc. stock logo
NVAX
Novavax
-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.380.30%N/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.380.30%N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.05%+2.50%121.99%16 Years
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
$0.140.17%N/AN/AN/A

Latest IBB, XBI, MRNA, PFE, NVAX, and IBB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
3/17/2025
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.12123/18/20253/18/20253/21/2025
3/17/2025
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.12123/18/20253/18/20253/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A44.15 millionN/AOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A44.15 millionN/AOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990160.84 million158.58 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable
SPDR S&P Biotech ETF stock logo
XBI
SPDR S&P Biotech ETF
N/A63.53 millionN/ANot Optionable

Recent News About These Companies

SPDR S&P Biotech ETF Experiences Big Inflow
Friday's ETF Movers: XBI, COPX
SPDR S&P Dividend ETF (SDY): How to Buy
Can Health Care ETFs Aid Your Portfolio?
XBI: Diverse Holding Amid Strong Catalysts, Buy
3 Biotech Stocks With Notable Insider Buying
Trade Tracker: Joe Terranova buys the XBI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$126.58 +1.83 (+1.47%)
As of 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$126.58 +1.83 (+1.47%)
As of 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Moderna stock logo

Moderna NASDAQ:MRNA

$28.54 +0.72 (+2.59%)
As of 04:00 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.67 +0.25 (+3.89%)
As of 04:00 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$24.41 +0.62 (+2.61%)
As of 03:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

SPDR S&P Biotech ETF stock logo

SPDR S&P Biotech ETF NYSEARCA:XBI

$82.95 +1.07 (+1.31%)
As of 04:10 PM Eastern

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.